Genetic polymorphisms associated with risk of venous thromboembolism in multiple myeloma patients treated with thalidomide.

• Authors: ALMÁŠI Martina; ŠEVČÍKOVÁ Sabina; SLABÝ Ondřej; ŠVÁCHOVÁ Hana; POUR Luděk; KAISAROVA Petra; HÁJEK Roman
• Year of publication: 2011
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: Venous thromboembolism (VTE) is a common side-effect of thalidomide treatment in patients with multiple myeloma (MM). In our retrospective study, we analyzed candidate single-nucleotide polymorphisms (SNPs) - CINP (rs7011), CETP (rs289747), ALDH1A1 (rs610529), CDKN1A (rs3829963), GAN (rs2608555), VEGF (rs699947) and ALDH1A1 (rs168351). Further studies are needed to confirm the initial analysis that provided predictive information of genetic variations in myeloma patients that may influence risk of VTE.

Related projects

• University Research Centre - Czech Myeloma Group
• From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies